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Major depressive disorder
TERMINOLOGY
CLINICAL CLARIFICATION
Major depressive disorder is a chronic and relapsing disease, characterized by a pervasive sad mood and the loss of
pleasure in most activities (anhedonia) persisting for at least 2 weeks 1
•
CLASSIFICATION
DSM-5 diagnostic classification states that major depressive disorder presents with at least 5 of the following 9
symptoms: 2
•
Depressed mood or anhedonia (patient must have at least 1; present most of the day nearly every day for a minimum
of 2 consecutive weeks)
○
Sleep disturbance○
Change in appetite or weight○
Psychomotor problems○
Lack of energy○
Poor concentration○
Feelings of worthlessness or guilt○
Suicidal ideation○
Symptoms cause clinically significant distress or impairment in social, work, or other areas of functioning•
Episode is not attributable to the physiologic effects of a substance or other medical disorder•
DIAGNOSIS
CLINICAL PRESENTATION
History•
Patients do not always present with a straightforward complaint of feeling depressed 3○
Vague somatic complaints or numerous complaints that do not fit any clear clinical pattern often occur, particularly in
elderly patients and in patients for whom psychological symptoms are stigmatized 3
○
Fatigue–
Poor concentration–
Memory impairment–
Difficulty making day-to-day decisions–
Decline in school or work performance–
Decreased sexual interest–
Sleep disturbance–
Appetite changes–
Weight changes (gain or loss)–
Headache–
Nausea–
Pain–
Change in bowel habits (constipation or diarrhea)–
Depressive symptoms 3○
Loss of interest or pleasure in previously enjoyable things–
Disproportionate feelings of guilt or thoughts of worthlessness–
Suicidal thoughts or thoughts about dying–
Psychotic symptoms (particularly in elderly patients)–
Anxiety and worry–
Preoccupation with physical complaints–
Physical examination•
Psychological findings 3○
Depressed or flat affect–
Appears withdrawn, with poor eye contact–
Psychomotor agitation or retardation–
Crying–
Anxious behavior–
Irritability–
Evidence of self-neglect with poor personal hygiene–
Dermatologic findings 3○
Evidence of self-harm (eg, healed lacerations, scars on body or extremities)–
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Weight loss, weight gain, or evidence of poor nutrition 3○
CAUSES AND RISK FACTORS
Causes•
Unknown○
Risk factors and/or associations•
Age 1○
Median age of onset is 32 years–
Overall prevalence is low until early adolescence–
Sex 1○
Women are twice as likely as men to experience major depressive disorder, regardless of racial background, ethnic
background, or socioeconomic status
–
Times of hormonal fluctuation convey the greatest risk□
Genetics 1○
Major depressive disorder is a multifactorial disorder with genetic susceptibility–
Greatest risk for major depressive disorder is observed in families with early age at onset 4□
Ethnicity/race 1○
Higher incidence in black and Hispanic populations compared with white populations–
Other risk factors/associations 1○
History of childhood maltreatment in any form–
Early parental loss (for women)–
DIAGNOSTIC PROCEDURES
Primary diagnostic tools•
Depression screening tools (eg, Beck Depression Inventory, Patient Health Questionnaire-9) can be used initially to
identify patients requiring full diagnostic interviews using standard diagnostic criteria 5, 6, 7, 8
○
History and physical examination provide definitive diagnosis○
Laboratory analyses (eg, hypothyroidism testing [TSH], urine or serum drug screen) can be used to exclude medical
disorders that produce or exacerbate mood symptoms or screen for substance-induced mood symptoms 9
○
Other diagnostic tools•
Standardized depression inventory tests○
United States Preventive Services Task Force recommends the following: "All positive screening results should lead
to additional assessment that considers severity of depression and comorbid psychological problems (eg, anxiety,
panic attacks, or substance abuse), alternate diagnoses, and medical conditions" 5
–
Beck Depression Inventory 8–
Self-rated questionnaire□
Measures the intensity, severity, and depth of common depression symptoms□
Standard test has 21 questions; a shorter 7-question version is optimized for screening use in the office setting□
Hamilton Depression Rating Scale 8–
Observer-rated scale designed to be administered by the health care professional□
Major Depression Inventory 7–
Self-rated questionnaire□
Incorporates both the ICD10 symptoms of depression and the DSM-IV symptoms of major depression□
Patient Health Questionnaire-9 10, 6–
Self-rated questionnaire with 9 items□
DIFFERENTIAL DIAGNOSIS
Most common 11•
Persistent depressive disorder (dysthymia)○
Characterized by:–
Changes in eating□
Altered sleeping pattern (eg, insomnia, hypersomnia)□
Low energy□
Low self-esteem□
Inability to concentrate or make decisions□
Feelings of hopelessness or pessimism□
Fewer symptoms than major depressive disorder–
Involves feeling depressed for periods of variable duration, but without meeting DSM-5 criteria for major depressive
disorder
–
Such patients often have major depressive disorder interspersed throughout their lifetime–
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Differentiated based on history and physical examination–
Bipolar disorder 12○
Mood disorder characterized by episodes of mania or hypomania–
Carefully screen patients with major depression for bipolar disorder–
15% of patients with major depression have bipolar disorder 13□
Patients with bipolar disorder do not respond to antidepressants; therefore, differentiation is crucial□
Presence of mania or hypomania is the cardinal feature that distinguishes bipolar disorder from major depressive
disorder
–
Mania□
A period of mood change (happy, excited, or irritable) that causes impairment and is distinct and noted by
others
□
At least 4 of the following symptoms are present:□
Inflated self-esteem or grandiosity□
Little need for sleep (without the development of fatigue)□
Pressured or overly verbose speech□
Racing thoughts□
Distractibility□
Irritability or agitation□
Reckless or high-risk behavior□
Differentiated based on history and physical examination–
Adjustment disorder 14○
Temporary, short-term, nonpsychotic response to an event or situation, such as a divorce, death in the family, a
disappointment, or a failure
–
Symptoms can include sadness, anxiety, insomnia, poor concentration, poor performance in school–
Symptoms persist for no longer than 6 months after termination of the stressor–
Does not meet criteria for another mental disorder–
Differentiated based on history and physical examination–
Dementia 15○
Especially in elderly patients, may be mistaken for major depressive disorder during early stages of the illness–
The following features are more closely associated with dementia:–
Impaired, inconsistent, and fluctuating orientation, mood, and behavior□
Cognitive impairment that worsens over time□
Neurologic deficits often present (eg, dysphasia, apraxia)□
Disabilities concealed by the patient□
Inability to remember recent events; often unaware of memory loss□
Onset of memory loss occurs before mood change□
Frequently uncooperative, confused, or disoriented□
Demonstrated lack of concern about cognitive deficit□
Differentiated based on history and physical examination–
Parkinson disease 16○
Progressive disorder of the central nervous system that often coexists with depression–
Associated with symptoms of major depressive disorder, in addition to:–
Increased muscle tone with cogwheel rigidity□
Coarse resting tremor□
Akinesia□
Loss of facial expression□
Shuffling gait□
Flexed posture□
Differentiated based on history and physical examination–
Schizophrenia○
Disorder that affects thoughts, feelings, and perceptions; primary symptom is psychosis with auditory hallucinations
and delusions
–
Schizophrenic patients may develop secondary major depression 17–
Distinguished from major depressive disorder by the following: 17–
Severe personality deterioration□
Thought disorder, including loose associations□
Grandiose delusions□
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Hallucinations, which are typically auditory□
Bizarre behavior□
Differentiated based on history and physical examination–
Hypothyroidism 18○
Patients with hypothyroidism may have symptoms of major depressive disorder, in addition to signs and symptoms
of slow metabolism (eg, dry skin, brittle hair, weight gain)
–
Differentiated by laboratory testing for hypothyroidism–
Substance use disorders○
May cause symptoms of depression with chronic use or from withdrawal–
Causative substances include:–
Alcohol□
Stimulants (eg, amphetamine, cocaine)□
Cannabis (with chronic use)□
Opiates□
Anabolic steroids□
Differentiated from major depressive disorder by:–
Positive result from urine or serum drug screen for the substance, if available□
History of mood disorder that occurs temporally with substance use or withdrawal□
Medication causes 10○
Drug classes that are known to produce symptoms similar to depression include:–
Benzodiazepines□
Steroids□
Levodopa□
Oral contraceptives□
Interferon□
Differentiated based on history and physical examination–
TREATMENT
GOALS 10
Assess the patient for suicidality and take steps to protect the patient as needed•
Reduce signs and symptoms, including residual symptoms 19, 20, 21•
Relieve any complications, such as malnutrition and substance abuse•
Restore prior level of psychosocial and occupational function•
Prevent relapse and recurrence•
DISPOSITION
Admission criteria 21•
Patients unable to take care of themselves at home○
Patients undergoing electroconvulsive therapy○
Suicidal/homicidal ideation with intention or overt suicide/homicide attempts○
Psychosis○
Recommendations for specialist referral•
Consult psychiatrist if the patient exhibits any of the following:○
Suicidal or homicidal ideation or attempts–
Severe confusion, raising the question of dementia or delirium–
Delusions or hallucinations–
Substance abuse or dependence–
Suspected bipolar disorder–
Depression that has not responded to appropriate drug therapy–
TREATMENT OPTIONS
Mild to moderate disease 22•
Psychotherapy is often adequate as initial therapy early in the disease course 23○
Use antidepressant medications for more severe or chronic disease○
Antidepressant medications are first line treatment for depression of any severity that has persisted for 2 years or
more 24
–
First line options include: 25, 23, 26–
Selective serotonin reuptake inhibitors 27□
Serotonin-norepinephrine reuptake inhibitors□
Published February 19, 2016; Updated April 30, 2019 
Copyright © 2020 Elsevier
Major depressive disorder
Noradrenergic and specific serotonin antidepressants□
Noradrenergic and dopaminergic antidepressants□
Second line options include: 24–
Tricyclic antidepressants□
MAOIs□
Consider combination therapy (ie, psychotherapy and medication) when the response to a single therapy is inadequate○
For most patients, combination therapy is more effective than either psychotherapy or antidepressant medication
alone; particularly for chronic or moderate to severe disease
–
Also consider for recurrent disease (with 3 or more episodes) 25–
Severe disease 22•
Drug therapy is required○
For most patients, combination therapy (psychotherapy and medication) is more effective than either psychotherapy
or antidepressant medication alone 25
○
If patient has a high risk of suicide or if welfare is threatened (eg, lack or nutrition or fluid intake), electroconvulsive
therapy will be necessary
○
Electroconvulsive therapy may be used as first line therapy for patients who have psychotic depression or catatonia
and patients who have previously responded to this treatment method
○
Relapse prevention 24•
Medication-responsive patients: continue medication at acute treatment dose after remission; use relapse risk to
determine medication duration
○
Patients at lower risk of relapse (eg, experiencing first episode without other risk factors): continue medication at
least 6 to 9 months after full remission 24, 25
–
Other patients: tailor medication duration to individual relapse risk–
Patients with any increased risk of relapse: continue medication at least 1 year after full remission 25□
Higher risk patients (eg, having more than 5 lifetime episodes and/or 2 episodes in the past few years): continue
medication for a minimum of 2 years; most will require long-term treatment
□
Patients with residual symptoms or at high risk of relapse: consider adding cognitive behavioral therapy to medication○
Patients who respond well to acute-phase cognitive behavioral therapy: it is not routinely recommended to continue
medication
○
Patients who are unstable or partial remitters (ie, patients in partial remission): continue cognitive behavioral therapy
or antidepressants
○
Patients who respond to acute-phase electroconvulsive therapy: continue or initiate prophylactic medication; consider
continuing electroconvulsive therapy in patients with frequent relapses who do not respond to prophylactic
medication
○
Esketamine nasal spray—the first NMDA (N-methyl-D-aspartate) receptor antagonist to receive FDA approval for major
depression—can be used as an adjunct to an oral antidepressant for treatment-resistant depression (those whose
condition has failed to respond to 2 or more standard antidepressant treatments) 28
•
Drug therapy•
Selective serotonin reuptake inhibitors 29○
Citalopram–
Citalopram Hydrobromide Oral tablet; Children and Adolescents 7 to 17 years: 10 mg PO once daily initially. Some
experts recommend initial doses of 20 mg/day PO in those 12 years and older. Clinical guidelines recommend to
start with a low dose and titrate gradually, in 10 mg/day increments at 4-week intervals until clinical response is
achieved. Some studies titrate as often as every week. A dose of 20 mg/day PO is considered effective. Max: 40
mg/day in the general population and 20 mg/day in poor metabolizers of CYP2C19 due to the potential for QT
prolongation. Coadministration of certain drugs may need to be avoided or dosage adjustments may be
necessary; review drug interactions.
□
Citalopram Hydrobromide Oral tablet; Adults 60 years and younger: Initially, 20 mg PO once daily; may increase to
40 mg PO once daily after 1 week if clinically indicated. Max: 40 mg/day in the general population and 20 mg/day
in poor metabolizers of CYP2C19 due to the potential for QT prolongation. Coadministration of certain drugs may
need to be avoided or dosage adjustments may be necessary; review drug interactions.
□
Citalopram Hydrobromide Oral tablet; Adults older than 60 years: 20 mg PO once daily is the recommended and
maximum daily dosage. Coadministration of certain drugs may need to be avoided or dosage adjustments may be
necessary; review drug interactions.
□
Escitalopram 30, 31–
Escitalopram Oral tablet; Children and Adolescents 12 to 17 years: The initial and recommended dose is 10 mg PO
once daily. If needed, may increase to 20 mg/day after a minimum of 3 weeks, but a trial in adults suggested no
additional benefit. Max: 20 mg/day PO. Periodically reassess the need for continued treatment.
□
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Escitalopram Oral tablet; Adults: 10 mg PO once daily is the initial and recommended dose. If needed, may
increase to 20 mg once daily after a minimum of 1 week, but one trial suggested no additional benefit. Max: 20
mg/day PO. Periodically reassess the need for continued treatment.
□
Escitalopram Oral tablet; Geriatric Adults: 10 mg PO once daily is the initial and recommended dose. Periodically
reassess the need for continued treatment.
□
Fluoxetine–
Fluoxetine Hydrochloride Oral tablet [Depression/Mood Disorders]; Children and Adolescents 8 to 17 years: 10 to
20 mg PO once daily. An initial dose of 10 mg/day may be appropriate in lower weight children; increase to 20
mg/day after 1 week. Usual effective dose: 10 to 20 mg/day. May increase by 10 to 20 mg increments if response
not sufficient; full effect may take 4 weeks or longer. Max: 60 mg/day. May divide daily dose into 2 doses (e.g.,
morning and noon) if the dosage is 20 mg/day or more.
□
Fluoxetine Hydrochloride Oral tablet [Depression/Mood Disorders]; Adults: 20 mg/day PO initially. May increase
after several weeks by 10 to 20 mg as needed and tolerated. Consider lower dosages for geriatric adults. Max: 80
mg/day PO. May divide daily dose into 2 doses (e.g., morning and noon) if the dosage is 20 mg/day or more.
□
Paroxetine–
Paroxetine Hydrochloride Oral tablet; Adults: 20 mg PO once daily initially, usually in the morning. May increase
by 10 mg at weekly intervals. Max: 50 mg/day PO. DEBILITATED ADULTS: 10 mg PO once daily initially, with
increases as needed by 10 mg at a minimum of weekly intervals up to a maximum of 40 mg/day PO. When
discontinuing, taper the dose if possible.
□
Paroxetine Hydrochloride Oral tablet; Geriatric Adults: 10 mg PO once daily initially. May increase by 10 mg at
weekly intervals. Max: 40 mg/day PO. When discontinuing, taper the dose if possible.
□
Sertraline 32–
Evidence recommends that physicians use caution when prescribing sertraline in pediatric patients (if at all)□
For children 6 to 11 years with major depressive disorder: do not recommend off-label sertraline; the harms of
the drug outweigh any benefits 33
□
For adolescents 12 to 17 years with major depressive disorder: 33□
First line treatment: to achieve a clinical response with minimal risk of suicidality, recommend cognitive
interventions first
□
Second line treatment: if cognitive interventions fail and adolescents are closely monitored for sertraline-
associated harms, may recommend off-label sertraline
□
Sertraline Hydrochloride Oral tablet; Children 6 to 11 years†: 12.5 mg to 25 mg/day PO initially. Begin with a low
dose and titrate gradually in 12.5 to 25 mg/day increments at 4-week intervals until clinical response is achieved;
some studies report titration in 25 mg to 50 mg/day increments as often as every 1 to 2 weeks. A dose of 50
mg/day PO is considered effective in some patients. Max: 200 mg/day PO.
□
Sertraline Hydrochloride Oral tablet; Children and Adolescents 12 to 17 years†: 25 to 50 mg/day PO initially. Begin
with a low dose and titrate gradually in 12.5 to 25 mg/day increments at 4-week intervals until clinical response is
achieved; some studies report titration in 25 mg to 50 mg/day increments as often as every 1 to 2 weeks. A dose
of 50 mg/day PO is considered effective in some patients. Max: 200 mg/day PO.
□
Sertraline Hydrochloride Oral tablet; Adults: 50 mg PO once daily. A lower initial dose (25 mg PO once daily) may
be used to minimize adverse effects. If necessary, increase at intervals of not less than 1 week. Max: 200 mg/day
PO. The length of treatment should be determined on an individual basis. Periodically reassess the need for
continued treatment.
□
Serotonin-norepinephrine reuptake inhibitors○
Duloxetine–
Duloxetine Oral capsule, gastro-resistant pellets; Adults: Initially, give 20 mg PO twice daily or 60 mg/day PO as a
single dose or in 2 divided doses (i.e., 30 mg PO twice daily). Alternatively, give 30 mg/day PO for 1 week, then
increase to 60 mg/day. Target maintenance dose: 60 mg/day; dividing doses may increase tolerability. Max: 120
mg/day PO, but more than 60 mg/day has not been shown to have an additional benefit.
□
Milnacipran–
Milnacipran Hydrochloride Oral tablet; Adults: Initially, 12.5 to 25 mg PO twice daily. Based on individual
response, the dose may be titrated to 100 mg PO twice daily. Max: 200 mg/day. In one trial of adult patients with
diabetes mellitus type 2 and co-morbid depression, 72.6% of treated patients fulfilled criteria for antidepressant
response according to the Beck Depression Inventory scale.
□
Venlafaxine–
Venlafaxine Hydrochloride Oral tablet; Adults: 75 mg/day PO, given in 2 or 3 divided doses, initially. If needed,
may increase by 75 mg/day no less than every 4 days. Outpatient Max: 225 mg/day PO, given in divided doses.
Institutional Max: 375 mg/day PO, given in 3 divided doses.
□
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Noradrenergic and specific serotonin antidepressants○
Mirtazapine 31–
Do not use concomitantly with MAOIs□
Mirtazapine Oral tablet; Adults: 15 mg PO once daily at bedtime, initially. If needed, may titrate no sooner than
every 1 to 2 weeks. Geriatric patients may need slower titration schedules. The effective dose range is 15 to 45
mg/day. Max: 45 mg/day PO.
□
Noradrenergic and dopaminergic antidepressants○
Bupropion–
Bupropion Hydrochloride Oral tablet [Depression/Mood Disorders]; Children† and Adolescents† 6 years and older:
Dosage not established. Suggested dosage ranges from 1.4 to 6 mg/kg/day PO, titrated upward slowly and
administered in divided doses. In trials, the average effective dose is roughly 3 mg/kg/day PO; the maximum
dosage is generally 250 to 300 mg/day PO. Safety data are not extensive; most patients have also been diagnosed
with ADHD.
□
Bupropion Hydrochloride Oral tablet [Depression/Mood Disorders]; Adults: Initially, 100 mg PO twice daily; titrate
after 3 days to 100 mg PO 3 times per day if needed; no single dose should exceed 150 mg.
□
Tricyclic antidepressants 29○
Amitriptyline–
Amitriptyline Hydrochloride Oral tablet; Adolescents: Begin at a low daily dosage, usually at bedtime, and titrate
as needed and tolerated. Lower doses are used compared to young adults; 10 mg PO 3 times per day with 20 mg
PO at bedtime may be satisfactory in adolescents who do not tolerate higher dosages. When satisfactory
improvement has occurred, reduce to the lowest effective dose. Weight-based dosing has been used in clinical
trials in adolescents for other indications. TCAs are not drugs of choice for pediatric patients with depression;
there is lack of high-quality data to support efficacy and safety.
□
Amitriptyline Hydrochloride Oral tablet; Adults: Initially, 75 mg/day PO, given in divided doses, or, 50 mg to 100
mg PO once daily at bedtime. Hospitalized patients may require 100 mg/day PO initially. Titrate if needed, up to
150 mg/day PO, by increasing the daily dose 25 to 50 mg at weekly intervals, to response and tolerance. Max
(hospitalized patients): 300 mg/day PO. Usual maintenance dose: 50 to 100 mg PO per day. In some patients, 40
mg/day PO is sufficient. For maintenance, give as a single dose, preferably at bedtime. Use lowest effective dose.
It is appropriate to continue maintenance therapy 3 months or longer to lessen the possibility of relapse.
□
Amitriptyline Hydrochloride Oral tablet; Geriatric: 10 to 25 mg PO at bedtime initially. Titrate as needed and
tolerated. Max: 150 mg/day PO, but such doses are not typically tolerated in the geriatric adult. Usual adult
maintenance dosage: 50 to 100 mg per day. In some patients, 40 mg/day is sufficient. For maintenance therapy,
give as a single dose, preferably at bedtime. Use lowest effective dose. It is appropriate to continue maintenance
therapy 3 months or longer to lessen the possibility of relapse.
□
Clomipramine–
Clomipramine Hydrochloride Oral capsule; Children and Adolescents 10 years and older: Initially, 25 mg PO once
daily, gradually increasing up to a total of 100 mg/day PO given in divided doses; or 3 mg/kg/day given in divided
doses, whichever is the smaller, over the first 2 weeks. In clinical trials in pediatric patients for OCD, the average
effective dose range was 100 to 200 mg/day.
□
Clomipramine Hydrochloride Oral capsule; Adults: Initially, 25 mg PO once daily, may gradually increase in the first
2 weeks to 100 mg/day PO, given in divided doses. Max: 250 mg/day. After titration, the total daily dose may be
given every night at bedtime to minimize daytime sedation.
□
Desipramine–
Desipramine Hydrochloride Oral tablet; Adolescents: 25 to 50 mg PO at bedtime initially. May titrate at weekly
intervals by 25to 50 mg, depending on response and tolerance. Usual Max: 100 mg/day PO, in single or divided
doses. Max (hospitalized patients): 150 mg/day PO. Once at a maintenance dosage, administering the total daily
dose at bedtime may minimize daytime sedation and improve compliance. TCAs are not drugs of choice for
pediatric patients with depression; there is lack of high-quality data to support efficacy and safety.
□
Desipramine Hydrochloride Oral tablet; Adults: 50 to 75 mg/day PO initially, in single or divided doses. Titrate by
25 to 50 mg at weekly intervals according to response and tolerance. The usual adult dose is 100 mg to 200 mg
PO per day, in single or divided doses. Max: 300 mg/day PO. Patients requiring up to 300 mg/day should generally
be hospitalized for therapy initiation. Once at a maintenance dosage, administering the total daily dose at
bedtime may minimize daytime sedation and improve compliance.
□
Desipramine Hydrochloride Oral tablet; Geriatric: 25 mg PO at bedtime initially. May titrate at weekly intervals by
25 to 50 mg, depending on response and tolerance. Usual max: 100 mg/day PO, in single or divided doses. Max
(hospitalized patients): 150 mg/day PO. Once at a maintenance dosage, administering the total daily dose at
bedtime may minimize daytime sedation and improve compliance.
□
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Imipramine–
Imipramine Hydrochloride Oral tablet; Adolescents: Initially, 30 mg to 40 mg/day PO once daily at bedtime to help
minimize daytime sedation. If necessary, titrate upward based on response and tolerability. Usual Max: 100
mg/day PO. Use the lowest effective dose that maintains remission. TCAs are not drugs of choice for pediatric
patients with depression; there is lack of high-quality data to support efficacy and safety.
□
Imipramine Hydrochloride Oral tablet; Adults: OUTPATIENTS: Initially, 75 mg/day PO; bedtime dosing may reduce
daytime sedation. The, titrate to 150 mg/day as a single dose or divided doses based on response and tolerability.
Optimal response may take 1 to 3 weeks of treatment at a given dose. Maintenance: 50 to 150 mg/day.
Outpatient Max: 200 mg/day PO. HOSPITALIZED ADULTS: Initially, 100 mg/day PO in divided doses, gradually
increased to 200 mg/day PO in divided doses as required. If no response after 2 weeks, increase to 250 mg/day to
300 mg/day PO. Hospitalized patient Max: 300 mg/day PO. Use lowest effective dose that maintains remission.
□
Imipramine Hydrochloride Oral tablet; Geriatric Adults: Initially, 30 mg to 40 mg/day PO once daily at bedtime to
help minimize daytime sedation. If necessary, titrate to response and tolerability. Usual Max: 100 mg/day. Use the
lowest effective dose that maintains remission.
□
Nortriptyline–
Nortriptyline Hydrochloride Oral capsule; Adolescents: Initially, 10 mg or 25 mg PO at bedtime.May increase as
tolerated to 30 mg to 50 mg per day, given in divided doses or once daily at bedtime. TCAs are not drugs of choice
for pediatric patients with depression; the quality of data to support efficacy and safety in adolescents is
considered marginal.
□
Nortriptyline Hydrochloride Oral capsule; Adults: Initially, 25 mg to 50 mg PO per day, given in divided doses or at
bedtime. May increase as needed and tolerated. Max: 150 mg/day PO.
□
Nortriptyline Hydrochloride Oral capsule; Geriatric Adults: Initially, 10 mg to 25 mg PO at bedtime. May increase
as tolerated to 30 mg to 50 mg per day, in divided doses or at bedtime.
□
MAOIs 34○
Avoid alcohol, tobacco, caffeine, and tyramine-containing foods (eg, aged cheeses, cured meats, fermented
cabbage, soy sauce, fava beans) except when taking selegiline at the lowest dosage
–
Isocarboxazid–
Isocarboxazid Oral tablet; Adolescents 16 years and older: In patients receiving contraindicated drugs known to
interact with MAOIs, the interacting drug should be discontinued for at least 1 to 2 weeks before initiating
isocarboxazid therapy. INITIAL DOSAGE: 10 mg PO twice daily. Carefully assess for drug efficacy and safety to
individualize dosage. May increase by 10 mg/day PO every 2 to 4 days, up to 40 mg/day PO by end of first week.
May increase further by up to 20 mg/week, if needed and tolerated. Max: 60 mg/day PO, given in 2 to 4 divided
doses. Use caution if receiving more than 40 mg/day PO. MAINTENANCE DOSAGE: After maximum clinical
response is achieved, reduce the dosage over several weeks to the lowest dosage that maintains effectiveness to
limit cumulative MAOI effects and serious dose-related toxicity. Periodically re-evaluate for drug effectiveness
and safety.
□
Isocarboxazid Oral tablet; Adults: In patients receiving contraindicated drugs known to interact with MAOIs, the
interacting drug should be discontinued for at least 1 to 2 weeks before initiating isocarboxazid therapy. INITIAL
DOSAGE: 10 mg PO twice daily. Carefully assess for drug efficacy and safety to individualize dosage. May increase
by 10 mg/day PO every 2 to 4 days, up to 40 mg/day PO by end of first week. May increase further by up to 20
mg/week, if needed and tolerated. Max: 60 mg/day PO, given in 2 to 4 divided doses. Use caution if receiving
more than 40 mg/day PO. MAINTENANCE DOSAGE: After maximum clinical response is achieved, reduce the
dosage over several weeks to the lowest dosage that maintains effectiveness to limit cumulative MAOI effects
and serious dose-related toxicity. Periodically re-evaluate for drug effectiveness and safety.
□
Phenelzine–
Phenelzine Sulfate Oral tablet; Adults: 15 mg PO 3 times daily; may rapidly increase to 60 mg/day if tolerated.
Individualize dosage based on careful observation. For some, an increase up to 90 mg/day may be necessary.
Onset of maximum effect is 2 to 6 weeks. After the maximum benefit is achieved, reduce dosage slowly over
several weeks to the lowest dose that maintains effectiveness. Maintenance dose may be as low as 15 mg/day PO
or 15 mg PO every other day, continued as long as required. NOTE: In patients requiring a contraindicated drug
known to interact with MAOIs, phenelzine should be discontinued for at least 2 weeks before initiating the
interacting drug.
□
Selegiline–
Selegiline Hydrochloride Transdermal patch - 24 hour; Adults: Initially, 6 mg/24 hours transdermally once daily. If
clinically indicated, increase by 3 mg/24 hour at intervals of no less than 2 weeks. Effective dose range: 6 to 12
mg/24 hours. Max: 12 mg/24 hours. Inform patients to avoid tyramine-containing foods/beverages/dietary
supplements beginning on the first day of selegiline 9 mg or 12 mg/24 hours treatment. Avoid tyramine for 2
weeks after dose reduction (to 6 mg/24 hours) or discontinuation of 9 mg/24 hours or 12 mg/24 hours.
□
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NMDA (N-methyl-D-aspartate) receptor antagonists○
Esketamine nasal spray 28–
First NMDA antagonist to receive FDA approval for major depression□
Used as an adjunct to an oral antidepressant for treatment-resistant depression (those who have failed 2 or more
standard antidepressant treatments)
□
Only available through a restricted distribution system, under a Risk Evaluation and Mitigation Strategy, owing to
risk of serious adverse outcomes resulting from sedation and dissociation and the potential for drug misuse
□
Esketamine intranasal dosage (ie, Spravato nasal spray containing 28 mg per device); Adults: INDUCTION PHASE:
On day 1, administer 56 mg intranasally. For subsequent doses during Weeks 1 through 4, administer 56 mg or 84
mg twice per week. Use 2 devices for the 56 mg dose and 3 devices for the 84 mg dose with a 5-minute rest
between use of each device. MAINTENANCE PHASE: During Weeks 5 through 8, administer 56 mg or 84 mg once
weekly. During Week 9 and thereafter, administer 56 mg or 84 mg every 2 weeks or once weekly. The dosing
frequency should be individualized to the least frequent dosing to maintain remission/response. 35
□
Nondrug and supportive care•
Music therapy○
Music therapy (provided by a music therapist) has been found to decrease depressive symptoms, improve anxiety
associated with major depressive disorder, and improve functioning 36
–
Acupuncture 37○
Small to moderate reduction in the severity of depressive symptoms has been reported–
Exercise 38○
Exercise has been shown to have significant effect in reducing depressive symptoms in patients with major
depressive disorder, 39 especially regular, moderate-level, aerobic exercise
–
Procedures○
Psychotherapy–
General explanation□
Includes cognitive behavioral therapy, behavioral activation therapy, interpersonal psychotherapy, problem-
solving therapy, nondirective counseling, and psychodynamic therapy 10
□
First line recommendations for acute major depressive disorder include cognitive-behavioral therapy,
interpersonal psychotherapy, and behavioral activation therapy 40
□
All types are known to be effective options 41, 10□
May be used as the initial treatment modality for patients with major depressive disorder, with or without
concomitant medication therapy; often adequate as initial therapy, early in the course of the disease 10
□
Cognitive behavioral therapy administered concurrently with medication may increase the rate of patient
response 40, 42
□
Cognitive behavioral therapy administered after medication is withdrawn may impart a protective effect
against relapse 42
□
Indication□
Significant psychological stressors, intrapsychic conflict, or interpersonal difficulties□
Mild to moderate depression 24□
Patients are more likely to respond to psychotherapy than to medication□
Electroconvulsive therapy 43–
General explanation□
Generalized seizures are intentionally induced using electrical impulses□
Typically performed 2 to 3 times per week until clinical response is seen□
Average course is 6 to 12 treatments, which are administered under anesthesia and with muscle relaxants□
Indication 44, 24□
May be used as first line therapy for patients who have:□
Psychotic depression□
Catatonia□
Previous response to this treatment method□
Severe suicidality□
Anorexia/rapidly deteriorating physical status□
Treatment-resistant depression□
Repeated medication intolerance□
Contraindications□
Relative contraindications□
Age younger than 18 years□
Space-occupying brain lesions□
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Elevated intracranial pressure□
Recent myocardial infarction□
History of retinal detachment□
Pheochromocytoma□
Complications□
Associated with transient postictal confusion and a period of antegrade and retrograde memory loss□
Can cause a transient rise in heart rate, in cardiac workload, and in blood pressure□
Repetitive transcranial magnetic stimulation 45–
General explanation□
Magnetic fields stimulate nerve cells in the brain to improve symptoms of depression□
Evaluate patients for seizure risk before repetitive transcranial magnetic stimulation, including: 46, 23□
Personal/family history of seizures or epilepsy□
Previous head injury or stroke with neurologic sequelae□
Current use of medications/substances that lower seizure threshold (eg, psychostimulants) or reduction in
dose of medication with antiseizure properties (eg, benzodiazepine)
□
Presence of medical condition or neurologic disorder that may lower seizure threshold (eg, electrolyte
imbalance, sleep deprivation, drug withdrawal)
□
Electromagnetic coil is held against the forehead and short electromagnetic pulses are administered through
the coil
□
Left prefrontal repetitive transcranial magnetic stimulation repeated daily for 4 to 6 weeks is an effective and
safe treatment in adult patients with unipolar major depressive disorder that has failed 1 or more
antidepressant trials 47
□
Typical session lasts 30 to 60 minutes and does not require anesthesia 46□
Indication□
First line treatment for patients with major depression who have not responded to antidepressant drug
therapy 44, 25
□
Contraindications□
Pregnancy□
Aneurysm clips□
Presence of other ferromagnetic material in the head, with the exception of the mouth□
Deep brain stimulator use (unintended currents can result)□
Complications 48□
Headache□
Scalp discomfort□
Seizures□
Comorbidities•
Anxiety disorder○
Approximately one-half of patients with anxiety disorders have other mood disorders (typically dysthymia or
depression) 49
–
Obsessive-compulsive disorder○
Often produces additional depression symptoms 50–
Substance abuse disorder (eg, alcohol, opioids, amphetamine, cocaine, cannabis)○
Associated with depression and suicide attempts–
Impulsivity is heightened when under the influence of substances 51–
Coronary artery disease○
Risk of future cardiac events is 2 to 3 times higher in patients with coronary artery disease and depression when
compared to patients without depression 52
–
Diabetes mellitus○
Patients with diabetes and depression experience worse glycemic control and an increased risk of diabetic
complications 53
–
Obesity○
Depression-associated low motivation, poor adherence, negative thinking, fatigue, and sleep problems reduce the
success of early-treatment weight loss programs 54
–
Special populations•
Pregnant women○
Untreated major depressive disorder in pregnancy poses a risk to the mother and fetus (potential harm from
malnutrition, poor prenatal care, substance abuse, or suicide attempts)
–
Published February 19, 2016; Updated April 30, 2019 
Copyright © 2020 Elsevier
Major depressive disorder
Treatment can include psychotherapy and medications determined by the patient's obstetrician and psychiatrist–
Given the potential harms to the fetus and newborn child from certain pharmacologic agents, clinicians are
encouraged to consider cognitive behavioral therapy or other evidence-based counseling interventions when
managing depression in pregnant or breastfeeding women 25, 5
□
MONITORING
During the initial phase of treatment, monitoring can vary from once per week to multiple times per week depending on
severity
•
American Academy of Pediatrics guidelines recommend that adolescents are assessed in person within 1 week of
treatment initiation 27
•
Frequency of monitoring can be based on severity, presence of suicidal ideation, patient adherence to treatment, social
supports, and coexisting medical conditions
•
COMPLICATIONS AND PROGNOSIS
COMPLICATIONS
Suicide•
Majority of patients with completed suicide have major depression○
Substance abuse•
PROGNOSIS
There is a high risk of relapse after a depressive episode, especially in the first 6 months; risk declines with time in
remission 24
•
Risk factors for relapse include presence of residual symptoms, number of previous episodes, severity, duration, and
degree of treatment resistance of the most recent episode
○
Untreated depression increases the risk of self-inflicted injury or suicide•
Prognosis of major depressive disorder in elderly patients is poor, as the majority of cases remain undetected 5•
SCREENING AND PREVENTION
SCREENING
At-risk populations•
United States Preventive Services Task Force recommends screening adults for major depression; the optimum interval
for screening is unknown 5
○
United States Preventive Services Task Force recommends screening adolescents aged 12 to 18 years for major
depressive disorder 55
○
American Academy of Pediatrics guidelines recommend that adolescent patients aged 12 years and older should be
screened annually for depression with a formal self-report screening tool 56
○
United States Department of Veterans Affairs recommends screening for major depression annually 10○
American College of Obstetricians and Gynecologists recommends patients be screened for depression and anxiety
symptoms at least once during the perinatal period, using a standardized, validated tool; screening for postpartum
depression and anxiety is also recommended, using a validated instrument 57
○
Screening tests•
Standardized depression inventory tests include Beck Depression Inventory, Major Depression Inventory, Hamilton
Depression Rating Scale, and Patient Health Questionnaire-9 5, 8, 7, 10
○
PREVENTION
SYNOPSIS
KEY POINTS
Major depressive disorder is a chronic and relapsing disease, characterized by a pervasive sad mood and the loss of
pleasure in most activities (anhedonia)
•
Rule out underlying physical illnesses that may mimic major depressive disorder (eg, hypothyroidism, dementia)•
Diagnosis relies on history and physical examination, as well as validated depression inventory tools 5 such as Beck
Depression Inventory, 8 Hamilton Depression Rating Scale, 8 Major Depression Inventory, 7 and Patient Health
Questionnaire-9 6
•
Psychotherapy is often adequate as initial therapy early in the course of the disease 22•
Use antidepressant medications for more severe or chronic disease 22•
Consider combination therapy (psychotherapy and medication) when the response to a single therapy is inadequate 22•
For severe disease, drug therapy is required, and for most patients combined therapy is more effective than either
psychotherapy or antidepressant medication alone 22
•
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If patient has a high risk of suicide or if welfare is threatened (eg, lack of nutrition or fluid intake), electroconvulsive
therapy will be necessary 22
•
Untreated depression increases the risk of self-inflicted injury or suicide•
URGENT ACTION
Suicidal ideation or suicide attempts require hospitalization and urgent evaluation by a psychiatrist•
PITFALLS
Even if major depressive disorder is diagnosed correctly, bipolar disorder may be present; treatment varies by disorder, so
differentiation is required
•
Always consider substance abuse as a potential contributor to major depressive disorder and a potential consequence of
it
•
Discontinuing medications that influence serotonin levels (particularly with short half-lives) can suddenly cause
antidepressant discontinuation syndrome:
•
Flulike symptoms (eg, nausea, vomiting, diarrhea, headaches)○
Sensory/movement disturbances (eg, vertigo, dizziness)○
Cognitive symptoms (eg, hyperarousal, confusion)○
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